Your search for tofacitinib returned 95 results

For patients with rheumatoid arthritis, a novel oral Janus kinase inhibitor, tofacitinib, is associated with reduced symptoms when used as monotherapy or in addition to background methotrexate.

Pfizer announced top-line results from ORAL Start (A3921069), a Phase 3 study of the investigational agent tofacitinib in the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA).

Pfizer announced that the FDA has accepted for review its New Drug Application (NDA) for tofacitinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). The NDA is based on previously completed Phase 3 trials.

Pfizer announced results from two of its Phase 3 studies, ORAL Standard and Oral Step, of tofacitinib (CP-690,550) for the treatment of active rheumatoid arthritis.

Pfizer announced results from its Phase 3 study of tofacitinib, formerly known as tasocitinib, for the treatment of patients with rheumatoid arthritis (RA).